Porcine Vaccines
Porcine Vaccines Market by Indication (Arthritis, Diarrhea, Porcine Circovirus Associated Disease), Technology (Conjugate Vaccines, DNA Vaccines, Inactivated Vaccines), End User - Global Forecast 2024-2030
360iResearch Analyst
SPEAK TO ANALYST? OR FACE-TO-FACE MEETING?
Want to know more about the porcine vaccines market or any specific requirement? Ketan helps you find what you're looking for.
DOWNLOAD A FREE PDF
This free PDF includes market data points, ranging from trend analysis to market estimates & forecasts. See for yourself.

[194 Pages Report] The Porcine Vaccines Market size was estimated at USD 1.71 billion in 2023 and expected to reach USD 1.82 billion in 2024, at a CAGR 6.72% to reach USD 2.70 billion by 2030.

Porcine vaccines are immunological preparations designed to prevent various swine diseases in pigs. These vaccines are created to stimulate the porcine immune system, enabling it to develop defenses against pathogens such as viruses or bacteria that can cause illness. By mimicking the infection, they prepare the swine’s body to recognize and combat the actual pathogens should they be encountered in the future. The rise in the incidence of swine diseases and the growing global consumption of pork products are major driving factors behind the need for porcine vaccines. Furthermore, supportive government initiatives, including subsidies and awareness programs, have encouraged the use of vaccines. However, the need for a cold chain infrastructure creates logistical challenges, particularly in developing countries. Furthermore, the variability in the immune response of different pig breeds can impact vaccine effectiveness and create hurdles for the development and adoption of porcine vaccines. However, key players are exploring novel technologies such as nanotechnology, gene editing strategies, and precision medicine to ensure the development of customized vaccines that can overcome the performance challenges of porcine vaccines. Moreover, investigating new adjuvants to enhance immune response without compromising safety and developing needle-free administration could improve vaccine uptake and reduce stress on animals.

Regional Insights

In the Americas region, particularly the U.S. and Canada, the porcine vaccine market is well-established due to the extensive pig farming industry and a strong emphasis on animal health management. The country sees a significant consumer need for vaccinations against prevalent diseases such as porcine reproductive and respiratory syndrome (PRRS), swine influenza, and others. Producers often adopt the latest vaccines, and purchasing behavior indicates a readiness to invest in advanced solutions for swine herds. Recent research in the U.S. has focused on developing vaccines with improved efficacy and longer immunity periods. Investments in biotechnology companies and government initiatives such as the Veterinary Biologics Program under the United States Department of Agriculture(USDA)-Animal & Plant Health Inspection Service(APHIS) reflect ongoing efforts to strengthen the sector. The EMEA countries represent a diverse market with stringent animal welfare and health regulations. The European consumer requires vaccines that comply with high safety standards, leading to a demand for quality-assured vaccines. The EU’s Horizon 2020 program has seen substantial investments in research addressing swine diseases, which propels the development of new and efficient vaccines. In the APAC region, China represents a highly evolved market for pig meat, thereby accentuating the need for porcine markets. India, with an emerging pig farming industry in the APAC region, presents a moderate but growing demand for porcine vaccines. Consumer needs revolve around affordable and accessible vaccines due to cost-sensitive purchasing behaviors. The government has been encouraging the growth of the swine industry through initiatives that provide support for vaccinations and animal health programs.

Porcine Vaccines Market
To learn more about this report, request a free PDF copy
Market Dynamics

The market dynamics represent an ever-changing landscape of the Porcine Vaccines Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

  • Market Drivers
    • Rise in Prevalence of Swine Diseases Worldwide
    • Increasing Demand for High-Quality Pork Meat
    • Government Initiatives to Support Animal Health
  • Market Restraints
    • High Cost of Porcine Vaccine Development and Complex Storage Issues
  • Market Opportunities
    • Technological Advancements in Porcine Vaccine
    • Favorable Investment Landscape For Production of Novel Porcine Vaccines
  • Market Challenges
    • Limited Availability and Awareness Along with Side Effects Associated with Porcine Vaccines
Market Segmentation Analysis
  • Technology: Growing innovations in recombinant vaccines due to advancements in genetic engineering and molecular biology technologies

    A conjugate vaccine refers to a vaccine that is composed of a polysaccharide antigen fused or conjugated to a carrier molecule. In porcine vaccines, they are used to target diseases where the pathogens have polysaccharide coatings, which are generally poorly immunogenic. Such vaccines are especially useful for targeting diseases caused by bacteria with polysaccharide capsules. DNA vaccines utilize genetic material to induce an immune response. When the genetic material enters the animal's cells, it is used to produce the antigen which in turn stimulates the immune system. These vaccines are still relatively novel in the veterinary field. Such vaccines may be preferred for their potential for rapid development and their ability to provide long-lasting immunity without the need for adjuvants. Inactivated vaccines contain pathogens that have been killed. They cannot cause an infection but still prompt an immune response. These vaccines are considered safe and stable. Live attenuated vaccines contain a live and weakened version of the pathogen. They closely mimic a natural infection and typically provide strong, long-lasting immunity. Recombinant vaccines use a piece of the pathogen (typically a protein) created using the techniques of genetic engineering. This component is used to stimulate an immune response without the risk of introducing a live pathogen. Toxoid vaccines are created by inactivating the toxins produced by certain bacteria. These vaccines are used to protect against diseases that are caused not by the bacteria itself, but by the toxins they produce. Toxoid vaccines are the preferred option when addressing illnesses where the primary concern is the bacterial toxin.

  • End User: Growing need for mass vaccination programs in the hog/pig production farm

    The hog/pig production farm sector includes entities involved in raising pigs primarily for meat production. The need for vaccines in such farms is driven by the requirement to maintain a disease-free environment, enhance growth performance of the animals, and ultimately increase farmer profitability. Hog and pig production farms typically require vaccines thar can address a wide spectrum of common swine diseases, such as porcine reproductive and respiratory syndrome (PRRS), swine influenza, and foot and mouth disease, among others. Veterinary clinics and hospitals cater to a broad range of animals, including pigs. These facilities generally encounter pigs and other swine for vaccinations as part of routine health checks or specific disease outbreaks. The vaccine preferences in this environment are for products with broad-spectrum efficacy and rapid onset of immunity. Since these facilities might be dealing with individual animals or small herds, they often prefer single-dose, easy-to-administer vaccines that are also available in smaller package sizes.

Market Disruption Analysis

The market disruption analysis delves into the core elements associated with market-influencing changes, including breakthrough technological advancements that introduce novel features, integration capabilities, regulatory shifts that could drive or restrain market growth, and the emergence of innovative market players challenging traditional paradigms. This analysis facilitates a competitive advantage by preparing players in the Porcine Vaccines Market to pre-emptively adapt to these market-influencing changes, enhances risk management by early identification of threats, informs calculated investment decisions, and drives innovation toward areas with the highest demand in the Porcine Vaccines Market.

Porter’s Five Forces Analysis

The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the Porcine Vaccines Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.

Value Chain & Critical Path Analysis

The value chain of the Porcine Vaccines Market encompasses all intermediate value addition activities, including raw materials used, product inception, and final delivery, aiding in identifying competitive advantages and improvement areas. Critical path analysis of the <> market identifies task sequences crucial for timely project completion, aiding resource allocation and bottleneck identification. Value chain and critical path analysis methods optimize efficiency, improve quality, enhance competitiveness, and increase profitability. Value chain analysis targets production inefficiencies, and critical path analysis ensures project timeliness. These analyses facilitate businesses in making informed decisions, responding to market demands swiftly, and achieving sustainable growth by optimizing operations and maximizing resource utilization.

Pricing Analysis

The pricing analysis comprehensively evaluates how a product or service is priced within the Porcine Vaccines Market. This evaluation encompasses various factors that impact the price of a product, including production costs, competition, demand, customer value perception, and changing margins. An essential aspect of this analysis is understanding price elasticity, which measures how sensitive the market for a product is to its price change. It provides insight into competitive pricing strategies, enabling businesses to position their products advantageously in the Porcine Vaccines Market.

Technology Analysis

The technology analysis involves evaluating the current and emerging technologies relevant to a specific industry or market. This analysis includes breakthrough trends across the value chain that directly define the future course of long-term profitability and overall advancement in the Porcine Vaccines Market.

Patent Analysis

The patent analysis involves evaluating patent filing trends, assessing patent ownership, analyzing the legal status and compliance, and collecting competitive intelligence from patents within the Porcine Vaccines Market and its parent industry. Analyzing the ownership of patents, assessing their legal status, and interpreting the patents to gather insights into competitors' technology strategies assist businesses in strategizing and optimizing product positioning and investment decisions.

Trade Analysis

The trade analysis of the Porcine Vaccines Market explores the complex interplay of import and export activities, emphasizing the critical role played by key trading nations. This analysis identifies geographical discrepancies in trade flows, offering a deep insight into regional disparities to identify geographic areas suitable for market expansion. A detailed analysis of the regulatory landscape focuses on tariffs, taxes, and customs procedures that significantly determine international trade flows. This analysis is crucial for understanding the overarching legal framework that businesses must navigate.

Regulatory Framework Analysis

The regulatory framework analysis for the Porcine Vaccines Market is essential for ensuring legal compliance, managing risks, shaping business strategies, fostering innovation, protecting consumers, accessing markets, maintaining reputation, and managing stakeholder relations. Regulatory frameworks shape business strategies and expansion initiatives, guiding informed decision-making processes. Furthermore, this analysis uncovers avenues for innovation within existing regulations or by advocating for regulatory changes to foster innovation.

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Porcine Vaccines Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Porcine Vaccines Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments
  • Zoetis Launches Circomax In The UK

    Zoetis has introduced CircoMax to the UK market, a vaccine designed to combat porcine circovirus type 2 (PCV2). This vaccine is formulated to target multiple strains of the virus, offering protection against genotypes PCV2a, PCV2b, and PCV2d. These genotypes represent the primary variants found within the UK’s pig population. The relevance of CircoMax is cemented by current research indicating a shift in the dominant genotypes over time, from PCV2a originally to PCV2b, and most recently to PCV2d, highlighting the dynamic nature of the virus. [Published On: 2023-10-13]

  • Merck Animal Health Launches 3-In-One Swine Vaccine

    Merck Animal Health announced the launch of Circumvent CML, a novel trivalent swine vaccine designed to combat key porcine diseases. Circumvent CML marks a significant advancement in swine health, delivering protection against porcine circovirus Type 2a (PCV-2a), porcine circovirus type 2d (PCV-2d), mycoplasma hyopneumoniae, and lawsonia intracellularis in one comprehensive formulation. This innovative vaccine encapsulates the effectiveness of Merck's established antigens and adjuvant systems, previously demonstrated in products such as Circumvent PCV-M G2 and Porcilis Ileitis, providing an integrated solution for swine producers. [Published On: 2023-06-14]

  • Elanco is Exclusive U.S. Distributor of Aptimmune’s PRRS Killed Autogenous Vaccine

    Elanco Animal Health Incorporated has secured an exclusive distribution agreement with Aptimmune Biologics, Inc. This arrangement positions Elanco as the sole provider of a novel porcine reproductive and respiratory syndrome (PRRS) vaccine, leveraging Aptimmune's innovative Barricade formula. This inactivated vaccine would complement Elanco's existing Prevacent PRRS live vaccine, thereby enhancing their portfolio of respiratory illness interventions. [Published On: 2023-05-13]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Porcine Vaccines Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Porcine Vaccines Market, highlighting leading vendors and their innovative profiles. These include Aptimmune Biologics, Inc., Arko Laboratories, AVAC Vietnam Joint Stock Company, Bayer AG, Bimeda Holdings PLC, Biogénesis Bagó S.A., Boehringer Ingelheim International GmbH, Ceva Sante Animale, Eli Lilly and Company, Endovac Animal Health, FATRO S.p.A., Formosa Biomedical Inc., Genvax Technologies, Inc., HIPRA, S.A., Indian Immunologicals Ltd., KM Biologics Co., Ltd., Kyoto Biken Laboratories, Inc., Malaysian Vaccines & Pharmaceuticals Sdn Bhd., Medgene Labs, Merck & Co., Inc., Nisseiken Co., Ltd., PBS Animal Health, Phibro Animal Health Corporation, Virbac SA, Yenher Agro-Products Sdn. Bhd., and Zoetis Inc..

Porcine Vaccines Market - Global Forecast 2024-2030
To learn more about this report, request a free PDF copy
Market Segmentation & Coverage

This research report categorizes the Porcine Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Indication
    • Arthritis
    • Diarrhea
    • Porcine Circovirus Associated Disease
    • Porcine Reproductive & Respiratory Syndrome
    • Swine Influenza
  • Technology
    • Conjugate Vaccines
    • DNA Vaccines
    • Inactivated Vaccines
    • Live attenuated Vaccines
    • Recombinant Vaccines
    • Toxoid Vaccines
  • End User
    • Hog/Pig Production Farm
    • Veterinary Clinics/Hospitals

  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

This research report offers invaluable insights into various crucial aspects of the Porcine Vaccines Market:

  1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
  2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
  3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
  4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
  5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current market size and projected growth?
  2. Which products, segments, applications, and regions offer promising investment opportunities?
  3. What are the prevailing technology trends and regulatory frameworks?
  4. What is the market share and positioning of the leading vendors?
  5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?

Table of Contents
  1. Preface
  2. Research Methodology
  3. Executive Summary
  4. Market Overview
  5. Market Insights
  6. Porcine Vaccines Market, by Indication
  7. Porcine Vaccines Market, by Technology
  8. Porcine Vaccines Market, by End User
  9. Americas Porcine Vaccines Market
  10. Asia-Pacific Porcine Vaccines Market
  11. Europe, Middle East & Africa Porcine Vaccines Market
  12. Competitive Landscape
  13. Competitive Portfolio
  14. List of Figures [Total: 22]
  15. List of Tables [Total: 294]
  16. List of Companies Mentioned [Total: 26]
Truly innovative porcine vaccines to safeguard the swine species
June 6, 2023
INSIGHT
Truly innovative porcine vaccines to safeguard the swine species
As disease pressure continues to sway the world's pig population and production, animal health companies seek ways to battle infections and lessen their impact by generating effective and inexpensive vaccines.

Swine diseases like porcine respiratory and reproductive syndrome (PRRS) and porcine epidemic diarrhea have caused massive losses and severely impacted the livestock breeding industry and public health.

Millions of pigs are culled following disease outbreaks in countries across the globe, making swine vaccines imperative to achieve healthier growth of pigs.

Injectable vaccines are proving to be a lifesaver for diseases that threaten the life of growing piglets and are typically given as soon as maternal antibody titers start to decline.

With the development of live vaccines, it is now possible to provide pigs with powerful immunity while lowering their risk of contracting infections.

The Vietnam and the United States government teamed up to create a pig vaccine for African swine disease. Also, governments from every corner of the world are devising animal health and pig vaccination programs that guard the herd against infectious diseases at all growth phases. Breakthrough techniques and methods for disease diagnostics, such as PCR and sequencing, are significantly advancing vaccine development.

Innovations in vaccine development and diagnostics, as well as novel vaccine techniques & tools and ongoing alliances for optimum vaccine production, are pushing animal health companies to maximize the production of porcine vaccines.

Porcine Vaccines: The Inevitable Scientific Advancement
October 25, 2023
BLOG
Porcine Vaccines: The Inevitable Scientific Advancement
Humans have always relied on the agriculture sector for food, clothing, and other essentials. Farming depends on effective methods and techniques to keep livestock and plants healthy and profitable. Keeping in view the importance of the pig population in the global economy and the potential risk of disease outbreaks in these animals, porcine vaccines are one of the most significant scientific advancements in agriculture. In the meantime, rapidly acquiring advances in biotechnology and molecular biology have allowed the development of modern and more effective vaccines that are highly specific to target infectious agents and are safer.

What are Porcine Vaccines?

Porcine vaccines refer to the vaccines that protect pigs against various contagious pathogens, known for their capacity to cause significant economic losses. These infectious agents can have a considerable impact on pork markets and supply chains around the world. The emergence of novel porcine viruses, such as African Swine fever and Porcine Epidemic Diarrhea (PED) in recent years, highlights the importance of vaccination. To date, many effective porcine vaccines are available globally, protecting against several viral and bacterial diseases such as porcine circovirus 2 (PCV2), swine influenza virus (SIV), Mycoplasma hyopneumoniae (MHyo), PRRS virus, Classical swine fever (CSF), Foot and Mouth Disease (FMD), among others.

Technological Advancements in Porcine Vaccines:

These vaccines are highly specific to target infectious agents and are safer. For example, many of the new-generation vaccines are based on recombinant technologies. Such vaccines include protein subunit vaccines, created by introducing parts of a pathogenic microorganism's proteins into another organism. Also, Virus-Like Particles (VLPs) technology mimics the natural virus particle and stimulates a protective immune response in the animal. Furthermore, the advent of DNA vaccines has revolutionized the field of immunology and vaccine development. These vaccines use portions of the pathogen's DNA to stimulate an immune response against the entire organism.

Advantages of Porcine Vaccination:

The following are the main advantages of porcine vaccination:

• Vaccination helps reduce the risk of morbidity and mortality, which is essential to increase herd health and production.

• Vaccines provide a cost-effective and practical measure of disease control, reducing the use of antibiotics by avoiding secondary infections and increasing animal welfare.

• Porcine vaccines protect the animals from infectious diseases and the producers' livelihoods from economic losses that can result from sickness and death.

• Vaccination also helps reduce the risk of zoonosis, a type of disease transmitted from animals to humans, ensuring the safety of consumers and producers.

Using porcine vaccines is an excellent way of controlling disease prevalence in pig populations. The technological advancements in biotechnology and molecular biology have allowed the development of modern and more efficient vaccines, providing more specific and safer products. Vaccination can control the occurrence of morbidity and mortality, reducing the use of antibiotics on farms. It ultimately enhances herd health, increases production, and decreases the economic burden on the pork industry. Vaccination can also minimize the risks of zoonoses, ensuring the safety of consumers and producers. The evolution of newly emerging diseases in pigs worldwide highlights the urgent need to develop novel and efficient vaccines.

Frequently Asked Questions
  1. How big is the Porcine Vaccines Market?
    Ans. The Global Porcine Vaccines Market size was estimated at USD 1.71 billion in 2023 and expected to reach USD 1.82 billion in 2024.
  2. What is the Porcine Vaccines Market growth?
    Ans. The Global Porcine Vaccines Market to grow USD 2.70 billion by 2030, at a CAGR of 6.72%
  3. When do I get the report?
    Ans. Most reports are fulfilled immediately. In some cases, it could take up to 2 business days.
  4. In what format does this report get delivered to me?
    Ans. We will send you an email with login credentials to access the report. You will also be able to download the pdf and excel.
  5. How long has 360iResearch been around?
    Ans. We are approaching our 7th anniversary in 2024!
  6. What if I have a question about your reports?
    Ans. Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available and included in every purchase to help our customers find the research they need-when they need it.
  7. Can I share this report with my team?
    Ans. Absolutely yes, with the purchase of additional user licenses.
  8. Can I use your research in my presentation?
    Ans. Absolutely yes, so long as the 360iResearch cited correctly.